Skip to content
VIDEO

Childhood Cancer Immunotherapy Program

VIDEO

New Childhood Brain Cancer Research

VIDEO

37 Years of Dedication

Video

Introducing the Telethon Kids Cancer Centre

VIDEO

Unlocking the key to leukaemia progression in kids

Today Tonight

The new sarcoma research team

video

Meet Finlay

VIDEO

The SJ Elliot Cancer Trial

May 2023

ONC201 in Combination with Paxalisib for the Treatment of H3K27-Altered Diffuse Midline Glioma

Diffuse midline gliomas (DMG), including diffuse intrinsic pontine gliomas (DIPG), are the most lethal of childhood cancers. Palliative radiotherapy is the only established treatment, with median patient survival of 9 to 11 months. ONC201 is a DRD2 antagonist and ClpP agonist that has shown preclinical and emerging clinical efficacy in DMG. 

Children's Cancers Published research Brain Tumour Research
March 2024

Pharmacokinetics of PEGasparaginase in Infants with Acute Lymphoblastic Leukemia

PEGasparaginase is known to be a critical drug for treating pediatric acute lymphoblastic leukemia (ALL), however, there is insufficient evidence to determine the optimal dose for infants who are less than one year of age at diagnosis. This international study was conducted to identify the pharmacokinetics of PEGasparaginase in infants with newly diagnosed ALL and gather insight into the clearance and dosing of this population.

Children's Cancers Published research Early Childhood Development Leukaemia Translational Research
February 2024

PI3K/mTOR is a therapeutically targetable genetic dependency in diffuse intrinsic pontine glioma

Diffuse midline glioma (DMG), including tumors diagnosed in the brainstem (diffuse intrinsic pontine glioma; DIPG), are uniformly fatal brain tumors that lack effective treatment.

Children's Cancers Published research Brain Tumour Research